CAR-T

Multiple myeloma
#Bristol Myers Squibb #CAR-T #Cell therapy #Immunotherapy #Japan #Myeloma

First CAR-T therapy approved for earlier use in treatment of myeloma

Bristol-Myers Squibb has received manufacturing and marketing approval in Japan for Abecma (idecabtagene vicleucel) as a third-line therapy for relapsed or refractory multiple myeloma (RRMM). Abecma is a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T cell immunotherapy. It is now approved for RRMM patients who have received at… Read More

#News #Regulatory

FDA headquarters
#Adverse event #Blood cancer #CAR-T #Cell therapy #FDA #Immunotherapy #Oncology

FDA investigates safety of CAR-T cell immunotherapies

The Food and Drug Administration (FDA) said it will investigate the safety of BCMA- or CD19-directed autologous CAR-T cell immunotherapies, following reports of T cell malignancies, including chimeric antigen receptor CAR-positive lymphoma, in these patients. The reports were received from clinical trials and postmarketing adverse event (AE) data sources. Despite… Read More

#News #Regulatory #Trending News

#Advanced Therapies #CAR-T #Cell and gene therapy #Cell therapy #Drug discovery #eBook #Gene therapy

DDW eBook: The latest innovations in cell and gene therapy

Hailed as a revolution in the treatment of many diseases, cell and gene therapy is the fastest growing area of therapeutics. This eBook, ‘Cell & Gene Therapy: The advances and innovation’, provides a comprehensive overview of the latest innovations in cell and gene therapies, where the… Read More

#News

#Advanced Therapies #CAR-T #Cell and gene therapy #Cell therapy #Drug discovery #eBook #Gene therapy

Cell & Gene Therapy: The advances and innovation

This 24-page eBook sponsored by Sartorius explores the latest innovations in cell and gene therapies, where the challenges lie and the possible solutions to overcoming these obstacles. Download this free resource to learn more about: The ways cell and gene therapies (CGTs) are revolutionising medicine in a range of diseases How… Read More

#DDW eBooks #Intelligence

#CAR-T #Cell and gene therapy #Cell therapy #CRISPR #Drug discovery #Gene therapy

New DDW Highlights podcast: 20 November 2023

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  The breaking news this week was certainly the first regulatory approval for… Read More

#News

#CAR-T #Cell and gene therapy #Cell therapy #CRISPR #Drug discovery #Gene therapy

This week in drug discovery (13-17 November) 

News round-up for 13-17 November by DDW Digital Content Editor Diana Spencer. The breaking news this week was certainly the first regulatory approval for Casgevy, not only the first gene therapy approved for sickle cell disease, but also the first therapy to use CRISPR gene editing. Read More

#News

Multiple myeloma
#Arcellx #CAR-T #Cell therapy #Clinical trial #Haematology #Myeloma #Oncology #Phase I trial

CART-ddBCMA trial shows durable response in myeloma patients

Arcellx has revealed encouraging interim data from its Phase I study of CART-ddBCMA in patients with relapsed or refractory multiple myeloma. The company plans to present new data with a median follow-up of 26.5 months at the 65th American Society of Hematology (ASH) Annual Meeting and… Read More

#Cancer Research #News

CAR-T therapy
#Cancer research #CAR-T #Cell therapy #EMA #Kite Pharma #Oncology #Phase III trial

CAR-T therapy Yescarta reduces risk of death by more than 27%

New trial evidence has shown that Kite’s CAR-T cell therapy Yescarta (axicabtagene ciloleucel: axi-cel) reduces the risk of death by 27.4% in patients with relapsed or refractory large B-cell lymphoma (R/R LBCL), corresponding to a 38% improvement in overall survival (OS). It is the only treatment in nearly 30 years… Read More

#Cancer Research #News #Regulatory

Lisbon skyline
#Biotherapeutics #CAR-T #Combination therapy #Drug targets #Engineered antibodies #Machine learning #PEGS Europe 2023

What to expect from PEGS Europe 2023: Day 2

Ahead of protein and antibody engineering conference PEGS Europe 2023 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting. On Day 2, Wednesday 15 November 2023, the tracks include: Engineering antibodies, emerging targets and therapeutic approaches, advancing bispecifics and combination… Read More

#Exclusive Content

#Antibody-based therapeutics #Artificial intelligence (AI) #CAR-T #Mergers and acquisitions #Microbiome #Partnership #Proteomics

Drug discovery deals highlight key growth areas

The latest acquisitions and strategic partnerships in the drug discovery and development sector reveal the areas where companies predict significant growth in the near future: proteomics, CAR-T, antibody discovery, artificial intelligence (AI) and microbiomics. Thermo Fisher Scientific acquires proteomics experts Olink Thermo Fisher Scientific will acquire proteomics company Olink in… Read More

#Business & Investment #News

CAR-T therapy
#Cancer research #CAR-T #CARsgen Therapeutics #China #Oncology #Solid tumours

CAR T therapy successfully treats solid tumours in China

CARsgen has published evidence of over seven years of disease-free survival in advanced hepatocellular carcinoma (HCC) following treatment with its CAR-GPC3 T cell therapy. Hepatocellular carcinoma is one of the most common malignant tumours, with approximately 780,000 annual incidence cases globally. Recurrence and metastasis are common. Read More

#Cancer Research #Editor's Choice #News

#Antibodies #Antibody drug conjugate (ADC) #CAR-T #Drug development #Drug discovery #Immunotherapy #Monoclonal antibodies

New DDW Highlights podcast: 2 October 2023

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  Immunotherapy has taken centre stage this week, with several announcements relating to… Read More

#News

#Antibodies #Antibody drug conjugate (ADC) #CAR-T #Drug development #Drug discovery #Immunotherapy #Monoclonal antibodies

This week in drug discovery (25-29 September)  

News round-up for 25-29 September by DDW Digital Content Editor Diana Spencer. Immunotherapy has taken centre stage this week, with several announcements relating to regulatory approval, investment and research results for antibody and CAR-T therapies, perhaps most significantly, encouraging early-stage data for the first in vivo… Read More

#News

CAR-T therapy
#Cancer research #CAR-T #Leucid Bio #MHRA #Oncology #Solid tumours

CAR-T therapy targets over 80% of human tumours

Leucid Bio has been granted clinical trial authorisation by the UK Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a Phase I/II clinical trial evaluating autologous NKG2D-targeted CAR-T cell therapy, LEU011, in patients with relapsed or refractory solid tumours. The open-label, single patient cohort ascending… Read More

#Cancer Research #Editor's Choice #News

T cells
#Cancer research #CAR-T #Immunotherapy #Oncology #T cell activation #Umoja Biopharma

Positive early-stage results for in vivo CAR-T technology

Umoja Biopharma has revealed data from an ongoing non-human primate (NHP) study demonstrating effective, durable, and well tolerated in vivo chimeric antigen receptor (CAR) T cell generation using the company’s VivoVec platform. The data include results from the first four NHPs treated in an ongoing study… Read More

#Cancer Research #News

CAR-T therapy
#Beam Therapeutics #Cancer research #CAR-T #Clinical trial #Leukaemia #Oncology #T cell activation

First base editing therapeutic for T-ALL/T-LL enters trials

The first quadruplex-edited, allogeneic CAR-T cell therapy candidate has entered clinical trials in the US. The first patient has been treated with Beam Therapeutics’ BEAM-201 as part of a Phase I/II clinical study for the treatment of relapsed/refractory T-cell acute lymphoblastic leukaemia/T-cell lymphoblastic lymphoma (T-ALL/T-LL). Read More

#Cancer Research #News